The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells
Open accessAbstract
Currently most attempts at cancer immunotherapy involve the generation of CD8+ cytotoxic T lymphocytes (CTLs) against tumor-associated antigens. Many tumors, however, have been immunoselected to evade recognition by CTLs and thus alternative approaches to cancer immunotherapy are urgently needed. Here we demonstrate that CD4+ T cells that recognize a secreted tumor-specific antigen and exhibit a cytokine secretion profile characteristic of Th2 cells, are capable of clearing established lung and visceral metastases of a CTL-resistant melanoma. Clearance of lung metastases by the Th2 cells was found to be totally dependent on the eosinophil chemokine, eotaxin, and partially dependent on the transcription activator signal transducer and activator of transcription 6 (STAT6), with degranulating eosinophils within the tumors inducing tumor regression. In contrast, tumor-specific CD4+ Th1 cells, that recruited macrophages into the tumors, had no effect on tumor growth. This work provides the basis for a new approach to adoptive T cell immunotherapy of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The expanding universe of T-cell subsets: Th1, Th2 and more
Mosmann, T. R., & Sad, S. (1996) · Immunology Today · doi:10.1016/0167-5699(96)80606-2 · Cited by 3,633
Essential role of Stat6 in IL-4 signalling
Takeda, K., Tanaka, T., Shi, W., Matsumoto, M., Minami, M., Kashiwamura, S.-I., Nakanishi, K., Yoshida, N., Kishimoto, T., & Akira, S. (1996) · Nature · doi:10.1038/380627a0 · Cited by 1,557 · cited 1×
“Furthermore, the reduced capacity of Th2 cells to eliminate tumors in STAT6-deficient mice is consistent with eotaxin playing an essential role in tumor clearance as eotaxin production by lung epithelial cells is largely dependent on signaling by the IL-4R–STAT6 pathway (21, 22).”
BackgroundThe IL-4 receptor: signaling mechanisms and biologic functions
Nelms, K., Keegan, A. D., Zamorano, J., Ryan, J. J., & Paul, W. E. (1999) · Annual Review of Immunology · doi:10.1146/annurev.immunol.17.1.701 · Cited by 1,545
The Central Role of CD4+ T Cells in the Antitumor Immune Response
Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., & Levitsky, H. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.12.2357 · Cited by 1,345
Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene
Shimoda, K., van Deursent, J., Sangster, M. Y., Sarawar, S. R., Carson, R. T., Tripp, R. A., Chu, C., Quelle, F. W., Nosaka, T., Vignali, D. A. A., et al. (1996) · Nature · doi:10.1038/380630a0 · Cited by 1,278 · cited 1×
“Furthermore, the reduced capacity of Th2 cells to eliminate tumors in STAT6-deficient mice is consistent with eotaxin playing an essential role in tumor clearance as eotaxin production by lung epithelial cells is largely dependent on signaling by the IL-4R–STAT6 pathway (21, 22).”
BackgroundAssociation of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma.
Leek, R., Lewis, C. E., Whitehouse, R. M., Greenall, M. J., Clarke, J., & Harris, A. L. (1996) · PubMed · Cited by 1,187
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Introduction of soluble protein into the class I pathway of antigen processing and presentation
Moore, M. W., Carbone, F. R., & Bevan, M. J. (1988) · Cell · doi:10.1016/s0092-8674(88)91043-4 · Cited by 1,092
Rothenberg, M. E. (1998) · New England Journal of Medicine · doi:10.1056/nejm199805283382206 · Cited by 834
Self-citationMurine interleukin-4 displays potent anti-tumor activity in vivo
Tepper, R. I., Pattengale, P. K., & Leder, P. (1989) · Cell · doi:10.1016/0092-8674(89)90925-2 · Cited by 778
Cited by
Smyth, M. J., Dunn, G. P., & Schreiber, R. D. (2006) · Advances in Immunology · doi:10.1016/s0065-2776(06)90001-7 · Cited by 870
Tumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845
CD4 and CD8 T lymphocyte interplay in controlling tumor growth
Ostroumov, D., Fekete-Drimusz, N., Saborowski, M., Kühnel, F., & Woller, N. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2686-7 · Cited by 549
Carretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Robust tumor immunity to melanoma mediated by interleukin-9–producing T cells
Purwar, R., Schlapbach, C., Xiao, S., Kang, H. S., Elyaman, W., Jiang, X., Jetten, A. M., Khoury, S. J., Fuhlbrigge, R. C., Kuchroo, V. K., et al. (2012) · Nature Medicine · doi:10.1038/nm.2856 · Cited by 442
Metadata
- Authors
- Mattes, J., Hulett, M., Xie, W., Hogan, S., Rothenberg, M. E., Foster, P., & Parish, C.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2003-01-27
- Volume
- 197
- Issue
- 3
- Pages
- 387-393
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W1964612175
- Cited by
- 256
- References
- 28
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells. https://app.cochat.ai/papers/10.1084/jem.20021683
- The paper
- Mattes, J., Hulett, M., Xie, W., Hogan, S., Rothenberg, M. E., Foster, P., & Parish, C. (2003). Immunotherapy of Cytotoxic T Cell–resistant Tumors by T Helper 2 Cells. The Journal of Experimental Medicine. https://doi.org/10.1084/jem.20021683
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.